MEN2312

Asset

Oral KAT6A and KAT6B inhibitor that blocks oestrogen-receptor signalling at the level of transcription

Stage: Phase 1
Modality: Small molecule
Target: KAT6A; 1
Indication: 1
Trial: 1
Developer

Indications

1

ER-positive HER2-negative breast cancer
Phase 1, Recruiting, NCT06638307, clinicaltrials.gov, 8 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners2
Trials1
Evidence for its targets1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.